4DMedical (ASX:4DX) Hits Record High on Tier-One Cleveland Clinic Deal

4DMedical Rockets to Record High

4DMedical (ASX: 4DX) has officially reached all time highs. We began writing on the company at A$0.25 per share and have since watched it evolve from a small cap into a business now valued at over A$1 billion, making it one of Australia’s strongest performing biotech companies. The latest 15% share price surge followed the announcement of a partnership with Cleveland Clinic, one of the most prestigious healthcare institutions globally, which will commence clinical trials under a research protocol.

This marks the company’s third major US academic medical centre partnership, following Stanford and Miami, and comes just three months after FDA approval. In our view, the speed at which these tier one institutions are engaging with 4DX speaks to growing clinical confidence in the technology and reinforces the company’s credibility at a critical stage of commercial adoption, while still leaving room for investors to assess execution risk as uptake scales.

What are the Best ASX Stocks to invest in?

Check our buy/sell tips

Why Cleveland Clinic matters as a customer

Cleveland Clinic is widely regarded as a top tier institution, consistently placing at the top of major hospital rankings, including the US Honor Roll and Newsweek’s global hospital rankings.

For investors, the practical significance of this partnership is less about near term revenue visibility, as no commercial agreement has been outlined yet, and more about credible adoption and clinical recognition of CT:VQ. Large academic medical centres often act as validation hubs, shaping broader hospital purchasing decisions, clinical protocols, and physician confidence, particularly when new technologies require changes to workflow and a high degree of clinician trust. In this context, Cleveland Clinic becomes a critical reference site for 4DMedical.

What CT:VQ is trying to replace or supplement

Ventilation perfusion imaging of the lungs is a long established diagnostic approach. Ventilation looks at how air flows through the lungs, while perfusion examines how blood travels through the lung vessels. Together, these measures allow doctors to diagnose a range of respiratory conditions. 4DMedical scans enable this dual functionality in a single scan, allowing clinicians to assess both ventilation and perfusion at the same time.

4DMedical’s value proposition centres on generating functional information and clinical interpretation of ventilation and perfusion from a standard CT chest scan. This is achieved through proprietary software designed to improve diagnostic logistics and streamline clinical workflows, rather than adding complexity to existing imaging processes.

The Investors Takeaway for 4DX

So for investors, even though the contract does not specifically mention a contract value, commercial development is structured around a land and expand model. This typically involves a short introductory period with low friction, where the technology is embedded into clinical use before transitioning to standard pricing. Investors can think of this as a practical trial phase. Importantly, the technology is being used directly within patient care pathways rather than limited to pre evaluation research trials, which materially strengthens the commercial signal.

From a valuation perspective, we always take a cautious stance when investing in stocks that have already experienced a sharp run. Using DroneShield as a recent example, extreme share price momentum can amplify downside risk even when the underlying business remains strong. While we continue to view 4DMedical as a compelling long term hold given its growth trajectory, more conservative investors should be mindful of near term volatility and may prefer to wait for a more attractive entry point if they are looking to gain exposure.